RVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 11:00 AM ET. The presentation will be available via webcast on the company's website. RVL will also participate in 1x1 investor meetings on the same day. The company specializes in UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), FDA-approved for treating acquired blepharoptosis in adults, marking the first non-surgical option for this condition.

BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at the H.C. Wainwright 24^th Annual Global Investment Conference as follows:

Date:		Monday, September 12, 2022
Time:		11:00AM ET
Webcast:		Click Here

The webcast will be available thereafter via the Company’s website www.rvlpharma.com under the “Investor & News” section.

RVL will be participating in 1x1 investor meetings on September 12. Meetings can be requested via H.C. Wainwright.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is believed to be the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Investor and Media Relations for RVL Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

IMPORTANT SAFETY INFORMATION

INDICATION

UPNEEQ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

WARNINGS AND PRECAUTIONS

• Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
• Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
• Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
• UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
• Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
  
  

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.

DRUG INTERACTIONS

• Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as betablockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
• Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

 

FAQ

When will RVLP present at the H.C. Wainwright Global Investment Conference?

RVLP will present on September 12, 2022, at 11:00 AM ET.

How can I access the RVLP presentation webcast?

The presentation can be accessed via the company's website after the event.

What is UPNEEQ and how is it related to RVLP?

UPNEEQ is an ophthalmic solution developed by RVLP for treating acquired blepharoptosis, approved by the FDA.

What are the main features of the H.C. Wainwright Conference for RVLP?

RVLP will participate in both a formal presentation and 1x1 investor meetings at the conference.

Where can I find more information about RVLP's investor relations?

Additional information is available on RVLP's official website under the 'Investor & News' section.